



Sanofi in China

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. **In 2016, Sanofi's net sales amounted to €33,821 million.**

Sanofi has a strong commitment to China. In 1982, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, Sanofi has around **9,000 employees in China** and is one of the fastest-growing healthcare companies in the country. Sanofi's China headquarters are in Shanghai, **supported by 11 branches** in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi.





A diversified healthcare company

► Pharmaceuticals

- **Chronic Diseases** – Sanofi is uniquely positioned to address public health needs in China with a broad portfolio of high-quality innovative medicines in such chronic diseases as cardiovascular diseases, diabetes, central nervous system diseases and oncology.
 - **Primary Care** – Sanofi is committed to improving access to healthcare. We deployed the first dedicated team in counties among multinational pharmaceutical companies in 2011 and launched the strategic Healthy Community Project in 2016.
 - **Rare Diseases** – Sanofi Genzyme is a global leader in rare diseases. Over the past 18 years, Sanofi Genzyme has helped more than 100 Chinese Gaucher disease patients through charitable programs. Sanofi Genzyme has been actively working with all parties to advance rare diseases treatment and patient access to innovative therapies, bringing hope to Chinese rare diseases patients.
- **Vaccines** – Sanofi Pasteur, the vaccines division of Sanofi, is a worldwide leader devoted entirely to human vaccines. With innovative vaccines preventing influenza, pneumococcal disease and pediatric infectious diseases, Sanofi Pasteur contributes to the advancement of disease prevention in China.
- **Consumer Healthcare** – In 2010, Sanofi entered the consumer healthcare market in China. In 2016, Sanofi and China Resources Sanjiu signed an agreement to establish a strategic partnership. The partnership encompasses a joint venture focusing primarily on pediatric and gynecological OTC products, as well as acts as a platform for future launches in China of other Sanofi Consumer Healthcare world-leading brands.

Industrial investment to meet the growing demand in China

Sanofi currently has three manufacturing facilities in Beijing (pharmaceutical), Hangzhou (pharmaceutical) and Shenzhen (vaccine).

Integrated and Collaborative R&D

Established in 2008, **Sanofi China R&D's capabilities span the entire R&D value chain, from drug target identification to late stage clinical trials.** With a commitment to bringing innovative drugs to China faster and more effectively, we focus on discovery research on Asia's most prevalent diseases, such as liver disease and diabetes, and leverage the growing biomedical ecosystem to develop new approaches such as translational medicine to fulfill Chinese patients' needs. Adopting an open innovation model, Sanofi China R&D has formed over 60 collaborations with China's top scientists and scientific institutions to date.



For more information, please visit www.sanofi.cn.